Louisville, Ky. | Pittsburgh
Join a SITC Professional Interest Community
Create new collaborations, build your professional network and discuss the latest research trends in SITC Professional Interest Communities.
The Journal for ImmunoTherapy of Cancer (JITC) received its first impact factor of 8.374! JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
See members discuss the benefits of a SITC membership in this new video.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
Brenda Ernest and Mirdula George I already e-know you from our other group, glad to see you here. Feel free to introduce yourself! Priscila ------------------------------ Priscila Goncalves Associate Director Center for Novel Cancer Therapies Northwell ...
Hi ladies Now that we enjoyed the SITC 2018 meeting in DC. Who is planning on going to the ASCO-SITC Meeting in Feb 2019 in San Fran. I would love to meet some of you in person and hear some of your ideas on how SITC can help our careers. Priscila ------------------------------ ...
The cited editorial states that even with modest survival benefits, tripling of PFS as related to the PACIFIC trial of use of durvalumab immediately after chemoradiotherapy is commendable. Given minimal side effects, its addition should be considered ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com